SCHEMBL5887181

SCHEMBL5887181

COc1ccc(CNC(=O)c2ccc(-n3c(=O)ccc4c(C)nc(N5CCN(c6ccc(O)cc6)CC5)nc43)cc2)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.45
GFER P55789 1/20 0.45
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 2/20 0.41
TLR9 Q9NR96 1/20 0.41
TLR8 Q9NR97 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
THRB P10828 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887644 0.94 NPC1 (0.45) NPC1GFERALDH1A1SMN1; SMN2RECQL
SCHEMBL5887045 0.94 SMN1; SMN2 (0.49) NPC1GFERALDH1A1SMN1; SMN2HSD17B10
SCHEMBL5887110 0.93 LMNA (0.46) NPC1GFERALDH1A1SMN1; SMN2MAPT
SCHEMBL5886714 0.92 ALDH1A1 (0.45) NPC1GFERALDH1A1SMN1; SMN2RECQL
SCHEMBL5886766 0.91 NPC1 (0.45) NPC1GFERALDH1A1SMN1; SMN2RECQL
SCHEMBL5886765 0.91 MAPT (0.48) NPC1GFERALDH1A1SMN1; SMN2RECQL
SCHEMBL5886825 0.91 NPC1 (0.45) NPC1GFERALDH1A1SMN1; SMN2RECQL
SCHEMBL5886820 0.90 SMN1; SMN2 (0.44) NPC1GFERALDH1A1SMN1; SMN2RECQL
SCHEMBL5887375 0.90 NPC1 (0.44) NPC1GFERALDH1A1SMN1; SMN2RECQL
SCHEMBL5886747 0.89 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2MAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP NPC1 4067/4885GFER 4505/4885ALDH1A1 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.